VCD Regimen Preferable as Induction for Newly Diagnosed Multiple Myeloma
the Cancer Therapy Advisor take:
Bortezomib, cyclophosphamide, and dexamethasone (VCD) is preferable to bortezomib, doxorubicin, and dexamethasone (PAd) as induction therapy for transplant-eligible patients with newly diagnosed multiple myeloma, a study published in the journal Leukemia has shown.
For the phase III trial, researchers enrolled 504 patients with newly diagnosed multiple myeloma who were eligible for stem cell transplantation. Patients either received VCD or PAd.
Results showed that 37.0% of patients in the VCD group achieved a very good partial response or better compared with 34.3% of patients in the PAd group (P = 0.001). In addition, 0.4% and 4.8% of those that received VCD and PAd, respectively, had progressive disease.
In regard to safety, serious overall adverse events and those related to thromboembolic events occurred more frequently in the PAd cohort (32.7% vs 24.0%; P = 0.04 and 2.8% vs 0.4%; P = 0.04). Neuropathy also occurred more frequently in the PAd group, while leukocytopenia and neutropenia occurred more commonly in the VCD arm.
The findings suggest that VCD is as effective as PAd and has a more favorable toxicity profile.
Bortezomib, cyclophosphamide, and dexamethasone is preferable as induction therapy for newly diagnosed multiple myeloma.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- NSCLC: Genetic Mutations May Determine Likelihood of Metastasis at Diagnosis
- Pembrolizumab Demonstrates Safety and Efficacy in Small-cell Lung Cancer
- FDA Grants Priority Review to Brentuximab sBLA for Cutaneous T Cell Lymphoma
- CAR T Cell Therapy for Acute Lymphoblastic Leukemia: An Evolutionary Perspective
- Statin-use May Decrease Mortality Risk in Prostate Cancer